Some of the reasons they're different are real:
In tech you're pretty sure you can build something, you're just not sure if anyone will buy it. In biotech you're pretty sure people will buy it, just not sure you can build it.
The challenges are far more complex (biology is a bitch) and require a LOT more domain specific knowledge to get traction.
It's necessarily highly regulated.
But things like people not giving younger founders a chance, and the lowballing on valuation don't need to be how things work. Hopefully people like Celine help turn that around.